Carolina Saleiro

Carolina Saleiro

Auto-generated profile, based on publicly available information

Carolina Saleiro

Pacing & Electrophysiology Unit, Cardiology Department Coimbra's Hospital and University Center Coimbra Portugal

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2020 in Journal of Cardiovascular Pharmacology and Therapeutics
Verified
Journal Article
Closed access
PDF file
CSCarolina Saleiro
Carolina Saleiro
JLJoão Lopes
João Lopes
DCDiana De Campos
Diana De Campos
LPLuís Puga
Luís Puga
MCMarco Costa
Marco Costa
RTRogério Teixeira
Rogério Teixeira
Background: Current guidelines recommend vitamin K antagonists (VKAs) for left ventricular thrombus (LVT) resolution. Direct oral anticoagulants (DOACs) are increasingly evaluated as alternatives to the standard of care in anticoagulation. Methods: We performed a systematic review and meta-analysis to assess the use of DOACs vs VKAs for LVT treatment. The occurrence of LVT resolution, systemic embolism (SE) or stroke, and bleeding events were compared during follow-up using random-effects analysis. Results: The 5 included studies were all observational (a total of 828 patients). Of these, 284 patients (34%) were treated with DOACs, and 544 (66%) treated with VKAs. Thrombus resolution was similar for both methods (pooled odds ratio [OR], 0.91; 95% CI, 0.47-1.75; I 2 = 63%; P = .78). The incidence of SE or stroke was also similar (pooled OR, 1.59; 95% CI, 0.85-2.97; I 2 = 0%; P = .14). Clinically relevant bleeding incidence was similar for both groups (pooled OR, 0.66; 95% CI, 0.31-1.40; I 2 = 0%; P = .28), although all bleeding events were less frequent in the DOAC group (pooled OR, 0.49; 95% CI, 0.26-0.90; I 2 = 0%; P = .02). Conclusion: Our systematic review and meta-analysis suggests DOACs were as effective as VKAs for LVT resolution, with a similar risk of systemic embolism/stroke and clinically relevant bleeding. These results, obtained from observational studies, are not definitive and hence randomized controlled trials are needed. Nevertheless, our analysis identifies key experimental features required in future studies.

11 November 2020 in Journal of Intensive Care
Verified
Journal Article
Open access
PDF file
CSCarolina Saleiro
Carolina Saleiro
RTRogério Teixeira
Rogério Teixeira
DCDiana De Campos
Diana De Campos
JLJoão Lopes
João Lopes
BOBárbara Oliveiros
Bárbara Oliveiros
LGLino Gonçalves
Lino Gonçalves
Background: Cardiogenic shock complicates 5–10% of myocardial infarction (MI) cases. Data about the benefit of glycoprotein IIb/IIIa inhibitors (GPI) in these patients is sparse and conflicting.Methods: We performed a systematic review, meta-analysis, and meta-regression of studies assessing the impact of GPI use in the setting of MI complicated cardiogenic shock on mortality, angiographic success, and bleeding events. We systematically searched for studies comparing GPI use as adjunctive treatment versus standard care in this setting. Random-effects meta-analysis and meta-regression were performed.Results: Seven studies with a total of 1216 patients (GPI group, 720 patients; standard care group, 496 patients) were included. GPI were associated with a 45% relative reduction in the odds of death at 30 days (pooled OR 0.55; 95% CI 0.35–0.85;I2= 57%;P= 0.007) and a 49% reduction in the odds of death at 1 year (pooled OR 0.51; 95% CI 0.32–0.82;I2= 58%;P= 0.005). Reduction in short-term mortality seemed to be more important before 2000, as this benefit disappears if only the more recent studies are analyzed. GPI were associated with a 2-fold increase in the probability of achieving TIMI 3 flow (pooled OR, 2.05; 95% CI 1.37–3.05;I2= 37%,P= 0.0004). Major bleeding events were not increased with GPI therapy (pooled OR, 1.0; 95% CI 0.55–1.83;I2= 1%,P= 0.99). Meta-regression identified that patients not receiving an intra-aortic balloon pump seemed to benefit the most from GPI use (Z= − 1.57,P= 0.005).Conclusion: GPI therapy as an adjunct to standard treatment in cardiogenic shock was associated with better outcomes, including both short- and long-term survival, without increasing the risk of bleeding.

2 June 2023 in EP Europace
Verified
Journal Article
Open access
PDF file
PSPedro A Sousa
Pedro A Sousa
SBSérgio Barra
Sérgio Barra
CSCarolina Saleiro
Carolina Saleiro
ZKZiad Khoueiry
Ziad Khoueiry
LALuís Adão
Luís Adão
LGLino Manuel Martins Gonçalves
Lino Manuel Martins Gonçalves
Pulmonary vein isolation (PVI) guided by the Ablation Index (AI) has shown high acute and mid-term efficacy in the treatment of paroxysmal atrial fibrillation (AF). Previous data before the AI-era had suggested that wide-area circumferential ablation (WACA) was preferable to ostial ablation. However, with the use of AI, we hypothesize that ostial circumferential ablation is non-inferior to WACA and can improve outcomes in paroxysmal AF. Prospective, multicentre, non-randomized, non-inferiority study of consecutive patients were referred for paroxysmal AF ablation from January 2020 to September 2021. All procedures were performed using the AI software, and patients were separated into two different groups: WACA vs. ostial circumferential ablation. Acute reconnection, procedural data, and 1-year arrhythmia recurrence were assessed. During the enrolment period, 162 patients (64% males, mean age of 60 ± 11 years) fulfilled the study inclusion criteria—81 patients [304 pulmonary vein (PV)] in the WACA group and 81 patients (301 PV) in the ostial group. Acute PV reconnection was identified in 7.9% [95% confidence interval (CI), 4.9–11.1%] of PVs in the WACA group compared with 3.3% (95% CI, 1.8–6.1%) of PVs in the ostial group [P < 0.001 for non-inferiority; adjusted odds ratio 0.51 (95% CI, 0.23–0.83), P = 0.05]. Patients in the WACA group had longer ablation (35 vs. 29 min, P = 0.001) and procedure (121 vs. 102 min, P < 0.001) times. No significant difference in arrhythmia recurrence was seen at 1-year of follow-up [11.1% in WACA vs. 9.9% in ostial, hazard ratio 1.13 (95% CI, 0.44–1.94), P = 0.80 for superiority]. In paroxysmal AF patients treated with tailored AI-guided PVI, ostial circumferential ablation is not inferior to WACA with regard to acute PV reconnection, while allowing quicker procedures with less ablation time. Distribution of acute pulmonary vein reconnection in both groups [wide-area circumferential ablation (WACA) vs. ostial] (central panel), with an illustration of the typical location for ablation lines in each corresponding group, in a posterior view (left panel). Ostial ablation was not inferior to WACA with regard to acute pulmonary vein reconnections (P < 0.001 for non-inferiority; P = 0.05 adjusted for superiority) and arrhythmia recurrence at 1-year of follow-up (P < 0.001 for non-inferiority; P = 0.80 for superiority), while requiring less ablation (P = 0.001) and allowing for quicker procedures (P < 0.001) (right panel).

3 September 2025 in Journal of Cardiovascular Electrophysiology
Verified
Journal Article
Open access
CSCarolina Saleiro
Carolina Saleiro
SBSérgio Barra
Sérgio Barra
BOBárbara Oliveiros
Bárbara Oliveiros
PAPatrícia Alves
Patrícia Alves
JFJoão Ferreira
João Ferreira
PSPedro A. Sousa
Pedro A. Sousa
Background: Pulmonary vein isolation (PVI) is the cornerstone of catheter ablation (CA) for atrial fibrillation (AF), yet outcomes remain suboptimal in persistent AF patients. Ethanol infusion in the vein of Marshal (VoM), an embryological remnant implicated in AF pathogenesis, may enhance ablation efficacy. Objective: To evaluate the effectiveness of VoM ethanol infusion in patients with persistent AF. Methods: We conducted a systematic review and meta‐analysis of randomized controlled trials (RCT) comparing CA with versus without VoM ethanol infusion in patients undergoing first‐time ablation of persistent AF. The primary endpoint was freedom from any atrial arrhythmia in a 12‐month follow‐up. Results: Four RCTs including 1045 patients were analyzed (VoM + CA—535 patients vs. CA alone—510 patients). Ethanol infusion in the VoM significantly increased freedom from atrial arrhythmias (RR 1.21; 95% CI 1.010–1.32; p < 0.0001, NNT 10) and reduced the need of a repeat procedure (RR 0.63; 95% CI 0.45–0.87; p = 0.005). Mitral isthmus (MI) block was more frequently achieved in the VoM group (RR 1.30; 95% CI 1.03–1.65; p = 0.03) There was no significant difference in the rate of major complications (2.8% vs. 3.5%, RR 0.72; 95% CI 0.37–1.43; p = 0.35, NNH 138), although overall complications were more frequent in the VoM ethanol infusion group (RR 2.25; 95% CI 1.08–4.70; p = 0.03). Conclusion: When added to CA, ethanol infusion in the VoM improves freedom from arrhythmia without increasing the risk of major complications. These findings may support its integration into ablation strategies for persistent AF.

1 January 2024 in Arquivos Brasileiros de Cardiologia
Verified
Journal Article
Open access
PDF file
APAndreia Palma
Andreia Palma
PSPedro A. Sousa
Pedro A. Sousa
CSCarolina Saleiro
Carolina Saleiro
SBSérgio Barra
Sérgio Barra
NANatália António
Natália António
LGLino Gonçalves
Lino Gonçalves
Resumo Fundamento: O software ablation index (AI) permitiu melhorar os resultados da ablação de fibrilação atrial (FA), mas as taxas de recorrência permanecem significativas. Biomarcadores séricos específicos têm sido associados a essa recorrência. Objetivos: Avaliar se certos biomarcadores podem ser utilizados (individualmente ou combinados) para predizer a recorrência de FA pós ablação guiada pelo AI. Métodos: Estudo multicêntrico, observacional, prospectivo de pacientes consecutivos, encaminhados para ablação de FA de janeiro de 2018 a março de 2021. Hemoglobina, peptídeo natriurético cerebral (BNP), proteína C reativa, troponina I ultrassensível, clearance de creatinina, Hormônio Tireoestimulante (TSH), e Tiroxina livre (T4) foram avaliados quanto à capacidade de prever a recorrência de arritmias durante o acompanhamento. Valores de p 1,8 μUI/mL [HR=1,82 (IC95%, 1,89-2,80), p=0,006] foi um preditor independente de recorrência. Avaliando-se a combinação de TSH, FT4 e BNP, a adição de cada valor “anormal” foi associada a uma menor sobrevida livre de recorrência (87,1% se nenhum vs. 83,5% se um vs. 75,1% se dois vs. 43,3% se três biomarcadores, p<0,001). Doentes com três biomarcadores “anormais” apresentaram três vezes maior probabilidade de recorrência de FA, comparativamente aos que não apresentaram nenhum biomarcador “anormal” (HR=2,88 [IC95%, 1,39-5,17], p=0,003). Conclusões: Quando combinados, valores anormais de TSH, FT4 e BNP podem ser uma ferramenta útil para prever a recorrência de FA pós ablação guiada pelo AI.

31 May 2024 in EP Europace
Verified
Journal Article
Open access
PDF file
PSPedro A Sousa
Pedro A Sousa
JTJohanna Tonko
Johanna Tonko
DDDagmara Dilling-Boer
Dagmara Dilling-Boer
SBSérgio Barra
Sérgio Barra
AEAnna-Sophie Eberl
Anna-Sophie Eberl
John SilberbauerJohn Silberbauer
John Silberbauer
Aims: We aimed to assess the acute and midterm efficacy of premature ventricular contraction (PVC) ablation guided by multielectrode and point-by-point (PbP) mapping. Methods and results: This is a retrospective, international multicentre study of consecutive patients referred for PVC ablation in 10 hospital centres from January 2017 to December 2021. Based on the mapping approach, two cohorts were identified: the ‘Multipolar group’, where a dedicated high-density mapping catheter was employed, and the ‘PbP group’, where mapping was performed with the ablation catheter. Procedural endpoints, safety, and acute (procedural) and midterm efficacies were assessed. Of the 698 patients included in this study, 592 received activation mapping [46% males, median age of 55 (41–65) years]—248 patients in the Multipolar group and 344 patients in the PbP group. A higher number of activation points [432 (217–843) vs. 95 (42–185), P < 0.001], reduced mapping time (40 ± 38 vs. 61 ± 50 min, P < 0.001), and shorter procedure time (124 ± 60 vs. 143 ± 63 min, P < 0.001) were reported in the Multipolar group. Both groups had high acute success rates (84.7% with Multipolar mapping vs. 81.3% with PbP mapping, P = 0.63), as well as midterm efficacy (83.4% vs. 77.4%, P = 0.08), with no significant differences in the risk of adverse events (6.0% vs. 3.5%, P = 0.24). However, for left-sided PVC ablation specifically, there was a higher midterm efficacy in the Multipolar group (80.7% vs. 69.5%, P = 0.04), with multipolar mapping being an independent predictor of success [adjusted OR = 2.231 (95% CI, 1.476–5.108), P = 0.02]. Conclusion: The acute and midterm efficacies of PVC ablation are high with both multipolar and PbP mapping, although the former allows for quicker procedures and may potentially improve the outcomes of left-sided PVC ablation.